United Kingdom Diabetes Drugs Market Insight
Published: 23 July 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The United Kingdom Diabetes Drugs Market is anticipated to grow at a CAGR of around 7.4% from 2025 to 2035, driven by the rising prevalence of type 2 diabetes, increasing obesity rates, expanding adoption of GLP-1 receptor agonists and SGLT2 inhibitors, and continued NHS initiatives supporting early diagnosis and disease management. Growing demand for innovative therapies and personalized diabetes care is expected to further accelerate market expansion.
United Kingdom Diabetes Drugs Market Forecasts to 2035
- The United Kingdom Diabetes Drugs Market Size was estimated at USD 2.94 Billion in 2025.
- The market is expected to grow at a CAGR of around 7.4% from 2025 to 2035.
- The United Kingdom Diabetes Drugs Market Size is expected to reach USD 6.00 Billion by 2035.
Notable Insights for the United Kingdom Diabetes Drugs Market
- Segmentation: Based on drug class, GLP-1 receptor agonists, SGLT2 inhibitors, and insulin therapies collectively accounted for nearly 71% of the market share in 2025, supported by growing clinical preference for advanced glucose-lowering treatments with cardiovascular and renal benefits.
- Segmentation: Based on distribution channel, hospital pharmacies, retail pharmacies, and online pharmacies represented approximately 76% of the market in 2025, reflecting increasing prescription volumes and improved patient access to chronic disease medications.
- Novo Nordisk A/S reported USD 42.34 billion in revenue during 2024, while Eli Lilly and Company generated USD 45.04 billion, highlighting their strong leadership in innovative diabetes therapies, GLP-1 medicines, and continuous investment in metabolic disease research.
- AstraZeneca PLC, Sanofi S.A., and Boehringer Ingelheim continue strengthening their diabetes portfolios across Europe. AstraZeneca reported USD 54.07 billion in revenue during 2024, reflecting its expanding presence in cardiovascular, renal, and metabolic disease therapeutics.
Download the eBook (ToC)
Why Buy This Report
- Provides a comprehensive assessment of the United Kingdom diabetes drugs market, including disease prevalence, treatment trends, innovative drug classes, reimbursement policies, and long-term growth opportunities.
- Delivers valuable insights into insulin therapies, oral antidiabetic drugs, GLP-1 receptor agonists, SGLT2 inhibitors, emerging biologics, and digital diabetes management solutions.
- Assists pharmaceutical manufacturers, healthcare providers, investors, distributors, and policymakers in identifying market opportunities, evaluating competition, and supporting strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom diabetes drugs market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Diabetes Drugs Market
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi S.A.
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Merck & Co., Inc.
- Bayer AG
- Abbott Laboratories
- Pfizer Inc.
- Johnson & Johnson.
Recent Developments:
- In November 2024, Eli Lilly and Company launched Mounjaro (tirzepatide) in additional NHS treatment pathways across the United Kingdom, expanding access for eligible adults with type 2 diabetes through broader clinical adoption.
- In September 2024, Novo Nordisk collaborated with the NHS and healthcare partners to strengthen obesity and diabetes management programs, supporting wider access to GLP-1 therapies and integrated patient care services across the United Kingdom.
Market Segmentation:
United Kingdom Diabetes Drugs Market, By Drug Class
- Insulin
- GLP-1 Receptor Agonists
- SGLT2 Inhibitors
- DPP-4 Inhibitors
- Biguanides
- Sulfonylureas
- Others
United Kingdom Diabetes Drugs Market, By Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
United Kingdom Diabetes Drugs Market, By Route of Administration
- Oral
- Injectable
United Kingdom Diabetes Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
United Kingdom Diabetes Drugs Market, By End User
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
Expert Views:
The United Kingdom diabetes drugs market is expected to witness steady growth through 2035, supported by increasing diabetes prevalence, broader adoption of innovative GLP-1 and SGLT2 therapies, and continuous NHS investment in chronic disease management. Pharmaceutical companies focusing on next-generation metabolic treatments, improved patient adherence, and value-based healthcare solutions are expected to strengthen their competitive position as demand for effective diabetes management continues to rise.
Author: Govind and Krishna By Decisions Advisors and Consulting